Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates news across four distinct healthcare sectors: medical devices, diagnostics, nutrition, and pharmaceuticals. This diversification produces a steady flow of announcements spanning FDA approvals for cardiac devices and diabetes technology, clinical trial results, product launches, and quarterly earnings reports.
Abbott's medical devices business drives significant news volume through regulatory clearances for cardiovascular implants, continuous glucose monitoring innovations, and structural heart interventions. The FreeStyle Libre platform and cardiac rhythm management portfolio generate regular updates on expanded indications, international approvals, and clinical evidence supporting device efficacy.
Quarterly earnings releases reveal segment-by-segment performance across Abbott's four divisions, providing insight into medical device adoption rates, diagnostic testing volumes, nutrition product demand, and emerging market pharmaceutical sales. As a Dividend Aristocrat with more than five decades of consecutive dividend increases, Abbott's dividend announcements attract income-focused investor attention.
Product development news includes CE Mark approvals for European markets, FDA 510(k) clearances, breakthrough device designations, and clinical study enrollments. Abbott's global manufacturing footprint and commercial presence in over 160 countries means regulatory and market access news spans multiple geographic regions.
Bookmark this page to follow Abbott's medical device innovations, diagnostic technology advancements, nutrition product developments, and financial performance updates as they are announced.
Ra Medical Systems has completed a stock-for-stock merger with Catheter Precision, aimed at enhancing its cardiac electrophysiology market presence. David Jenkins, CEO of Catheter Precision, will serve as Executive Chairman. The transaction includes a conversion of $25 million in debt to non-voting Convertible Preferred Stock, granting Catheter Precision stakeholders approximately 87.7% of RMED’s equity. Ra Medical anticipates raising up to
Abbott has partnered with Blood Centers of America to launch a pioneering mixed reality experience aimed at enhancing the blood donation process. This innovative technology, showcased at CES 2023, uses eye tracking to create an engaging digital environment for donors, addressing the decline in donations among younger individuals. Currently in pilot at select locations, this initiative seeks to improve the overall donation experience while ensuring donor safety. The initiative targets increasing the donation rate among the under-30 demographic, which has seen a significant decline.
Abbott (NYSE: ABT) is set to release its fourth-quarter 2022 financial results on January 25, 2023, prior to market opening. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. CT (9 a.m. ET), accessible via Abbott's Investor Relations website. Abbott is a leading global healthcare firm with a diverse portfolio, including diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a workforce of approximately 113,000 employees.
Abbott has announced that its FreeStyle Libre 3 sensor is now integrated with the mylife™ Loop automated insulin delivery (AID) system, marking a significant advancement in diabetes management. This innovative system, available in Germany and expanding to other European countries in 2023, automates insulin delivery based on real-time glucose data, simplifying diabetes care. Currently, this solution is not available in the United States. With over 4.5 million users, Abbott aims to enhance glucose control, helping many regain lost healthy years due to inadequate diabetes management.
Abbott (NYSE: ABT) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11 a.m. Central time. The presentation will be led by Robert B. Ford, chairman and CEO. A live webcast will be available on Abbott's Investor Relations website, with an archived version accessible later the same day. Abbott is a leading global healthcare company committed to enhancing lives through its diverse portfolio, impacting over 160 countries with approximately 113,000 employees.
Abbott has received FDA approval for its Eterna spinal cord stimulation (SCS) system, designed to treat chronic pain. This device is the smallest rechargeable spinal cord stimulator on the market, requiring as few as five recharges annually, significantly optimizing patient comfort. Eterna employs Abbott's BurstDR stimulation technology, which has been clinically proven to alleviate pain more effectively than traditional methods. With over 50 million Americans affected by chronic pain, Abbott aims to enhance healthcare delivery and improve patient outcomes through innovative solutions.
Abbott (NYSE: ABT) and the Brain Injury Association of America have co-founded Concussion Awareness Now, a coalition of nearly 20 advocacy groups aimed at increasing awareness about concussions. The initiative emphasizes the importance of diagnosis and treatment, with over half of individuals suspecting a concussion neglecting to seek care. Actress Rebel Wilson, who recently experienced a concussion, shares her story to support the cause. The coalition aims to change societal perceptions surrounding concussions and encourage proper medical attention.
Abbott (NYSE: ABT) announced an 8.5% increase in its quarterly dividend, raising it to 51 cents per share. This marks the company’s 51st consecutive year of dividend growth and the 396th consecutive quarterly dividend, to be paid on Feb. 15, 2023, to shareholders of record by Jan. 13, 2023. Abbott is recognized in the S&P 500 Dividend Aristocrats Index for consistent annual dividend increases over at least 25 years, reflecting its commitment to sustainable growth and shareholder returns.
Abbott (NYSE: ABT) has won three CES 2023 Innovation Awards from the Consumer Technology Association for its innovative health technologies. The awarded products include the Aveir VR Leadless Pacemaker, the Proclaim Plus SCS System, and the Alinity m Monkeypox PCR test. Abbott's achievements continue as the company was previously recognized for its FreeStyle Libre technology, named the best medical technology of the last 50 years by the Galien Foundation. This recognition underscores Abbott's commitment to advancing healthcare solutions globally.
Surmodics announced positive results from the 24-month follow-up of its TRANSCEND clinical trial at the VIVA conference in Las Vegas. The study involved 446 patients and compared the SurVeil DCB with the leading IN.PACT Admiral DCB. Results show that SurVeil achieved a primary patency rate of 70.8% versus 70.4% for IN.PACT, with comparable safety profiles. SurVeil uses a significantly lower dose of paclitaxel, which may enhance patient outcomes. Surmodics holds a partnership with Abbott (ABT) for commercialization upon FDA approval.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
